sitagliptin glp 1 agonist Structure of native GLP-1, exenatide, liraglutide, sitagliptin, and Mechanism of action of glucagon-like

They can reduce hepatic steatosis (fat accumulation in the liver), which is a characteristic of non-alcoholic fatty liver disease (NAFLD)

Neither study showed a significant increase in amylase (7% for both studies) or lipase (28% in the LEADER trial and 31% in the SCALE trial) values after starting liraglutide compared with placebo, and the positive predictive values of amylase and lipase for pancreatitis were less than 1%

Download the graphics below to share about this topic

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

Trends Mol